AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates include AB-SA01, AB-PA01 and AB-CD01.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NYSE:APHB
- CUSIP: N/A
- Web: www.ampliphibio.com
- Market Cap: $7.12 million
- Outstanding Shares: 6,627,000
- 50 Day Moving Avg: $1.92
- 200 Day Moving Avg: $0.99
- 52 Week Range: $0.67 - $38.25
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.10
- P/E Growth: 0.000
- Annual Revenue: $182,999.00
- Price / Sales: 38.93
- Book Value: $4.03 per share
- Price / Book: 0.27
- EBIDTA: ($12,290,000.00)
- Net Margins: -11,193.10%
- Return on Equity: -159.06%
- Return on Assets: -80.13%
- Average Volume: 1.01 million shs.
- Short Ratio: 1.65
Frequently Asked Questions for Ampliphi Biosciences Corp (NYSE:APHB)
What is Ampliphi Biosciences Corp's stock symbol?
Ampliphi Biosciences Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "APHB."
How were Ampliphi Biosciences Corp's earnings last quarter?
Ampliphi Biosciences Corp (NYSE:APHB) released its quarterly earnings results on Monday, August, 15th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.66) by $0.12. Ampliphi Biosciences Corp had a negative net margin of 11,193.10% and a negative return on equity of 159.06%. View Ampliphi Biosciences Corp's Earnings History.
Where is Ampliphi Biosciences Corp's stock going? Where will Ampliphi Biosciences Corp's stock price be in 2017?
1 brokers have issued 1 year price objectives for Ampliphi Biosciences Corp's shares. Their predictions range from $10.00 to $10.00. On average, they anticipate Ampliphi Biosciences Corp's share price to reach $10.00 in the next twelve months. View Analyst Ratings for Ampliphi Biosciences Corp.
Are investors shorting Ampliphi Biosciences Corp?
Ampliphi Biosciences Corp saw a drop in short interest in June. As of June 30th, there was short interest totalling 552,900 shares, a drop of 6.3% from the June 15th total of 590,027 shares. Based on an average daily volume of 279,917 shares, the short-interest ratio is presently 2.0 days. Approximately 6.6% of the company's shares are short sold.
Who are some of Ampliphi Biosciences Corp's key competitors?
Some companies that are related to Ampliphi Biosciences Corp include OncoGenex Pharmaceuticals (OGXI), Roka Bioscience (ROKA), Jaguar Animal Health (JAGX), Repros Therapeutics (RPRX), Transgenomic (PRPO), Metabolix (YTEN), Akers Biosciences (AKR), Ixico Plc (IXI), Synairgen plc (SNG), Rosetta Genomics (ROSG), Anacor Pharmaceuticals (ANAC), ANI Pharmaceuticals (BPAX), Celator Pharmaceuticals (CPXX), Cellular Dynamics International (ICEL), Covance (CVD), Cyprotex plc (CRX), GenVec (GNVC) and ImmunoCellular Therapeutics Ltd (IMUC).
Who are Ampliphi Biosciences Corp's key executives?
Ampliphi Biosciences Corp's management team includes the folowing people:
- Jeremy Laurence Curnock-Cook, Chairman of the Board
- Paul C. Grint M.D., Chief Executive Officer, Director
- Steven Robert Martin, Chief Financial Officer
- Igor P. Bilinsky Ph.D., Chief Operating Officer, Senior Vice President
- Louis C. Drapeau CPA, Director
- Wendy S. Johnson, Director
- Michael S. Perry Ph.D., Director
- Vijay B. Samant, Director
How do I buy Ampliphi Biosciences Corp stock?
Shares of Ampliphi Biosciences Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ampliphi Biosciences Corp's stock price today?
MarketBeat Community Rating for Ampliphi Biosciences Corp (NYSE APHB)MarketBeat's community ratings are surveys of what our community members think about Ampliphi Biosciences Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Ampliphi Biosciences Corp stock can currently be purchased for approximately $1.08.
Consensus Ratings for Ampliphi Biosciences Corp (NYSE:APHB) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$10.00 (830.23% upside)|
Analysts' Ratings History for Ampliphi Biosciences Corp (NYSE:APHB)
(Data available from 7/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|1/24/2017||Roth Capital||Reiterated Rating||Buy||N/A|
|3/8/2016||Griffin Securities||Reiterated Rating||Buy||N/A|
Earnings History for Ampliphi Biosciences Corp (NYSE:APHB)Earnings History by Quarter for Ampliphi Biosciences Corp (NYSE APHB)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Ampliphi Biosciences Corp (NYSE:APHB)
Current Year EPS Consensus Estimate: $-10.600 EPS
Next Year EPS Consensus Estimate: $-11.200 EPS
Dividend History for Ampliphi Biosciences Corp (NYSE:APHB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ampliphi Biosciences Corp (NYSE:APHB)Insider Trades by Quarter for Ampliphi Biosciences Corp (NYSE:APHB)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/29/2016||Randal J Kirk||Major Shareholder||Sell||177,020||$0.48||$84,969.60|| |
|4/8/2016||Jeremy Curnock Cook||Director||Buy||239,753||$2.36||$565,817.08|| |
|10/6/2015||Louis Drapeau||Director||Buy||10,000||$4.39||$43,900.00|| |
|10/5/2015||Michael Scott Salka||CEO||Buy||4,200||$4.75||$19,950.00|| |
|10/5/2015||Wendy S Johnson||Insider||Buy||1,000||$4.43||$4,430.00|| |
|3/16/2015||Randal J Kirk||Major Shareholder||Buy||13,939,392||$0.17||$2,369,696.64|| |
Headline Trends for Ampliphi Biosciences Corp (NYSE:APHB)
Latest Headlines for Ampliphi Biosciences Corp (NYSE:APHB)
Ampliphi Biosciences Corp (APHB) Chart for Sunday, July, 23, 2017